Evercore ISI analyst Elizabeth Anderson initiated coverage of Quest Diagnostics with an In Line rating and $159 price target. Quest, as the largest independent lab testing service provider in the U.S., is "an indispensable part of the U.S. healthcare system," Evercore tells investors. The firm forecasts topline growth and margin expansion upside over the medium term despite Quest’s scale, driven by industry consolidation and an improving operating environment, but points to the current valuation as a reason for staying on the sidelines.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on DGX:
- Quest Diagnostics price target raised to $154 from $143 at Baird
- Doctors gain confidence in new Alzheimer’s blood tests, Bloomberg reports
- Quest Diagnostics price target raised to $165 from $160 at Mizuho
- Quest Diagnostics partners with Northern Light Health in Maine
- Quest Diagnostics awarded group purchasing agreement by Premier